KalVista Pharmaceuticals (KALV) Depreciation & Amortization (CF) (2016 - 2025)
KalVista Pharmaceuticals' Depreciation & Amortization (CF) history spans 10 years, with the latest figure at $220000.0 for Q2 2025.
- On a quarterly basis, Depreciation & Amortization (CF) rose 8.37% to $220000.0 in Q2 2025 year-over-year; TTM through Apr 2025 was $671000.0, a 16.12% decrease, with the full-year FY2025 number at $900000.0, up 12.5% from a year prior.
- Depreciation & Amortization (CF) hit $220000.0 in Q2 2025 for KalVista Pharmaceuticals, down from $227000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for KALV hit a ceiling of $227000.0 in Q4 2024 and a floor of $193000.0 in Q3 2023.
- Historically, Depreciation & Amortization (CF) has averaged $210142.9 across 3 years, with a median of $207000.0 in 2024.
- Biggest five-year swings in Depreciation & Amortization (CF): grew 16.06% in 2024 and later grew 8.37% in 2025.
- Tracing KALV's Depreciation & Amortization (CF) over 3 years: stood at $197000.0 in 2023, then rose by 15.23% to $227000.0 in 2024, then decreased by 3.08% to $220000.0 in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for KALV at $220000.0 in Q2 2025, $227000.0 in Q4 2024, and $224000.0 in Q3 2024.